A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease (NCT06603246)
A Phase Ic, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Inhaled GDC-6988 in Patients With Muco-obstructive Disease
🩺 Plain-English Summary (8th-Grade Level)
This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- University of Alabama at Birmingham — Birmingham, Alabama
- Accel Research Site - Achieve - Birmingham - ERN - PPDS — Vestavia Hills, Alabama
- Stanford Center for Excellence in Pulmonary Biology — Palo Alto, California
- University of Kansas Medical Center-Kansas City-3901 Rainbow Blvd — Kansas City, Kansas
- University of North Carolina Clinical Research Center — Chapel Hill, North Carolina
- UPMC Montefiore Hospital — Pittsburgh, Pennsylvania
- TTS Research — Boerne, Texas
📞 Contact the Study Coordinator
Phone: (888) 662-6728
Email: global-roche-genentech-trials@gene.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-cystic Fibrosis Bronchiectasis
- A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis — Birmingham, Alabama
- A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis — Plantation, Florida
- Breathing Training and Exercise Capacity in Non-CFB — Jacksonville, Florida
Explore by condition: All Non-cystic Fibrosis Bronchiectasis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.